Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.41 USD
-1.25 (-0.91%)
Updated May 31, 2024 04:00 PM ET
After-Market: $135.49 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NBIX 135.41 -1.25(-0.91%)
Will NBIX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
Other News for NBIX
Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Affimed (AFMD)
Neurocrine Biosciences to Participate at Investor Conferences in June
Oppenheimer Reaffirms Their Buy Rating on Neurocrine (NBIX)
Neurocrine Biosciences Announces CEO Succession Plan
Neurocrine Biosciences to Present New Phase 3 CAHtalystâ„¢ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024